| Literature DB >> 30701264 |
Colin M McGill1, Timothy J Brown2,3, Lindsey N Fisher2, Sally J Gustafson4, Kriya L Dunlap4, Adam J Beck5, Paul T Toran6, David F Claxton2, Brian M Barth2,6.
Abstract
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with limited treatment options. Inflammation is often a contributing factor to the development and progression of AML, and related diseases, and can potentiate therapy failure. Previously, we had identified anti-inflammatory roles and anti-AML efficacy for blueberry extracts. The present study extended these observations to determine that the polyphenol quercetin inhibited neutral sphingomyelinase (N-SMase) activity and exerted anti-AML efficacy. Moreover, quercetin was shown to exert combinatorial anti-AML efficacy with nanoliposomal ceramide. Overall, this demonstrated that quercetin could block the pro-inflammatory actions of N-SMase and augment the efficacy of anti-AML therapeutics, including ceramide-based therapeutics.Entities:
Keywords: acute myeloid leukemia; blueberry; nanoliposomal ceramide; neutral sphingomyelinase; quercetin
Year: 2018 PMID: 30701264 PMCID: PMC6349237 DOI: 10.31021/ijbs.20181106
Source DB: PubMed Journal: Int J Biopharm Sci